NextBio and Genophen Form Partnership Aimed at Applying Genomics to Personalized Disease Prevention and Wellness
SANTA CLARA, Calif., April 2, 2013 -- NextBio and Genophen announced today a partnership aimed at furthering the adoption of genomics for disease prevention and wellness. The partnership enables Genophen to interpret full genome sequencing data from individuals through the use of the NextBio Clinical platform and to combine this data with a person's environmental, behavioral and clinical factors to create a uniquely tailored disease prevention and wellness plan for its individual members.
"Genophen is the first company to take lifestyle factors in synergy with genetic information derived from full genome sequencing to create a personalized health risk assessment and a set of recommendations for each individual," said Hossein Fakhrai-Rad , PhD, Co-Founder, Chief Executive Officer, and President of Genophen. "NextBio's vast and comprehensive repository of curated genomic and clinical data from the public domain adds depth to our analysis. This partnership with NextBio Clinical enables us to efficiently analyze and interpret whole genome data."
"Genophen's aim is to make the dream of personalized medicine a tangible reality," said Saeid Akhtari , President and CEO of NextBio. "Our partnership allows NextBio to take a first step towards the use of genomics for wellness and disease prevention, one of the ultimate goals of modern medicine."
Genophen has developed a healthcare software platform which assesses an individual's disease risks comprehensively and provides a personalized and actionable set of recommendations to keep individuals healthy, for longer. The risk assessment engine calculates health risks based on genetic, behavioral, environmental, and medical factors for multi-factorial diseases and it is targeted at disease prevention. The platform provides a deeply personalized set of recommendations that even specifies an individual's recommended food and physical activity based on their unique health conditions and genetic profile. The Genophen platform is a two-centric model, designed as a clinical tool for physicians with primary focus around delivery of care, and as a patient centric model to engage each individual in their own health.
NextBio provides a state of the art scientific platform to aggregate and interpret large quantities of molecular and other life sciences data for research and clinical applications. NextBio's platform integrates data from multiple repositories and diverse technologies by means of a unique correlation engine, which pre-computes billions of significant connections between disparate public and proprietary clinical and experimental data. This feature enables interpretation of an individual's molecular data. It also provides translational researchers the ability to look across the clinical and molecular data of entire populations for clinical trial stratification and selection, hypotheses generation, and biomarker discovery. NextBio Clinical, which recently passed an independent HIPAA audit, is designed for seamless integration with existing clinical and research systems. Backed by highly scalable, Big Data technology, it is capable of analyzing petabytes of data. NextBio's platform is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.
Today, NextBio is used by researchers and clinicians in over 50 top commercial and academic institutions including the National Institute of Health, The University of Southern California, Sanford-Burnham Medical Research Institute, Sanofi, Pfizer, Novartis, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Merck, Regeneron, GlaxosmithKline, Harvard Medical School, Scripps Research Institute, Stanford University, University of California at Berkeley, Takeda and many others. To learn more about NextBio, please visit our website at http://www.nextbio.com.